Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Conditions

• Head and Neck Squamous Cell Carcinoma (HNSCC)
• Pancreatic Adenocarcinoma
• Non-small Cell Lung Cancer (NSCLC)
• Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
• Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma
• Triple Negative Breast Cancer (TNBC)

Interventions

• DRUG: GTAEXS617
• DRUG: SoC

Sponsor

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.